Reviewer's report

**Title:** Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain

**Version:** 1  **Date:** 14 December 2011

**Reviewer:** Michael Pfaller

**Reviewer's report:**

This paper represents the 8th such analysis of the same data the only difference being that it is from the Spanish perspective. I have serious doubts that all of this "re-analysis/re-publishing" is necessary or useful except as a marketing ploy in each country. The rationale for so many different "perspective" publications should be clearly explained by the authors. The limitations of such modeling as it pertains to the real world must also be discussed. For example is an increase in life expectancy from 2.3 yrs to 2.5 yrs really a laudable goal?

**Level of interest:** An article of insufficient interest to warrant publication in a scientific/medical journal

**Quality of written English:** Acceptable

**Statistical review:** Yes, but I do not feel adequately qualified to assess the statistics.

**Declaration of competing interests:**

No competing interests